Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (206)	3/29/2002 6:27:22 PM
From: tuck	Read Replies (1) \| Respond to of 469

Wilder, I listened to the presentation and looked at the slides. The slides are clear about the patients being type 1s. The neurological symptoms they are seeing are different from those of type 2 and 3 patients, and unreported in the literature pertaining to type 1s (which the presenter seemed to acknowledge). I took this search to PubMed: "neurological + gaucher + type 1" and got three pages of hits including all types. There is a very clear distinction among the types. Type 1 is very clearly called "nonneurological," and such symptoms were unmentioned in the clinical abstracts I looked at. The patient populations in all studies are obviously small, but in aggregate are quite a bit bigger than what OGS has looked at. How did everyone else miss them? Is OGS looking harder? They might be. I own what for me is a lot of shares, and would like to be wrong, but . . . I really wonder if these effects they are seeing are "co-morbidities." My worry, apparently shared by Mr. Market, is that they are indeed from OGT918. Somebody please point out to me that I'm all wet here. Hopefully OGS' database will eventually do so, if no one else does; they are using a control group of untreated type 1s for comparative purposes. Cheers, Tuck